Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema

Next Previous
Trial Profile

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Patients With Diabetic Macular Edema

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; RG 6351 (Primary) ; Faricimab
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms THAMES
  • Sponsors Genentech; Roche

Most Recent Events

  • 28 Feb 2025 Planned End Date changed from 29 Sep 2024 to 30 Apr 2027.
  • 28 Feb 2025 Planned primary completion date changed to 30 Apr 2027.
  • 28 Feb 2025 Planned number of patients changed from 261 to 546.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top